This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. MOR, GMTX, CALT, ZYME, CMRX, CDMO, SBTX, RVNC, CKPT, and MBXShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Silverback Therapeutics (SBTX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical preparations" industry. IMARA vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Chimerix Avid Bioservices Silverback Therapeutics Revance Therapeutics Checkpoint Therapeutics MBX Biosciences IMARA (NASDAQ:IMRA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Do institutionals & insiders believe in IMRA or MOR? 49.3% of IMARA shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 37.3% of IMARA shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, IMRA or MOR? IMARA has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Does the media refer more to IMRA or MOR? In the previous week, IMARA and IMARA both had 1 articles in the media. IMARA's average media sentiment score of 0.00 beat MorphoSys' score of -0.71 indicating that IMARA is being referred to more favorably in the media. Company Overall Sentiment IMARA Neutral MorphoSys Negative Is IMRA or MOR more profitable? IMARA has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. IMARA's return on equity of 2.12% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets IMARAN/A 2.12% 2.00% MorphoSys -226.79%-694.31%-22.55% Which has stronger earnings and valuation, IMRA or MOR? IMARA has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMARAN/AN/A$1.49M$0.051,008.78MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 SummaryIMARA beats MorphoSys on 9 of the 11 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32B$784.70M$5.45B$8.93BDividend YieldN/A4.84%5.22%4.01%P/E Ratio1,008.991.3027.2420.06Price / SalesN/A230.50426.37117.54Price / Cash75.2423.4426.2128.59Price / Book14.666.237.925.56Net Income$1.49M-$27.94M$3.17B$248.56M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$50.44+1.0%N/AN/A$1.32BN/A1,008.9941MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$51.68+0.1%N/A+17.4%$2.24BN/A-51.6830CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.0528 of 5 stars$12.82+2.8%$21.00+63.8%+44.5%$891.98M$93.38M-8.55460CMRXChimerix0.6276 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6885 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeSBTXSilverback TherapeuticsN/A$16.57+4.9%N/A+81.5%$597.48MN/A-6.8583High Trading VolumeRVNCRevance Therapeutics2.7508 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.423 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210MBXMBX Biosciences3.0678 of 5 stars$11.05+13.6%$37.50+239.4%N/A$369.34MN/A0.0036 Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Chimerix Alternatives Avid Bioservices Alternatives Silverback Therapeutics Alternatives Revance Therapeutics Alternatives Checkpoint Therapeutics Alternatives MBX Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
